ArticleJournal of dental sciences2025
A retrospective analysis of oral autoimmune bullous diseases at a Thai oral medicine center.
Article in Journal of dental sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: / Materials and methods: Retrospective analysis of the characteristics, distribution, and treatment outcomes of oral AIBDs in Thai patients (20-year period). Results: Eighty-two oral AIBDs patients were diagnosed, mostly female ages ranging from middle-aged to elderly. The most common subtype was pemphigus vulgaris (PV) (59.8 %), followed by mucous membrane pemphigoid (MMP) (26.8 %), bullous pemphigoid (BP) (8.5 %), and linear IgA bullous dermatosis (LABD) (4.9 %). The gingiva was the most affected site. Notably, 81.8 % of MMP patients had only oral lesions (mostly gingiva), while most PV patients had multiple lesions, with oral lesions often appearing first. Corticosteroids (CS) (topical and/or systemic) were the primary treatment. The overall response rate for control of disease activity (CDA) was 73.9 %, with complete remission (CR) in 17.4 %. Patients receiving only topical CS had fewer side effects (66.7 % reported none, others mild) compared with combined therapy (48.6 % reported side effects). Conclusion: PV was the most prevalent subtype, often presenting with oral and skin lesions, with oral lesions appearing first. Conversely, MMP primarily manifested as isolated oral lesions, often with desquamative gingivitis. Combination therapy with topical and systemic CS was the most common treatment for oral AIBDs. Notably, patients treated with topical CS only experienced significantly fewer and milder side effects compared with those receiving other treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.